Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation

Not yet recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
COPD
Interventions
DIAGNOSTIC_TEST

Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI

Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.

All Listed Sponsors
collaborator

Temple University

OTHER

collaborator

University of Pennsylvania

OTHER

lead

Xemed LLC

INDUSTRY

NCT05816616 - Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation | Biotech Hunter | Biotech Hunter